Aside from the context of cancer, Hdm2 could also represent a new therapeutic target to stimulate skeletal muscle angiogenesis in chronic metabolic diseases associated with capillary regression such as obesity, diabetes, and limb ischemia. Here, MDM2 is linked to cancer.